Have any questions? 706-721-6582 or cts@augusta.edu
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)
Clinical Trial
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)
The purpose of this research study is to test the safety and effectiveness of the study drug, CVL-751-PD-001, in treating patients with early Parkinsons disease.
Eligibility Criteria
- Has been diagnosis Parkinsons Disease PD Patient is 40 to 80 years old
RESEARCH. INNOVATION. DISCOVERY.